We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Long-term Use of Bisphosphonates Lowers Risk of Colorectal Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Bisphosphonates, calcium-regulating drugs that inhibit bone resorption and used in the treatment of hypercalcemia and osteoporosis in humans, have been found to reduce the risk of developing colorectal cancer.

In addition to being used for treatment of osteoporosis, bisphosphonates are also used to treat bone metastases caused by breast cancer, and were recently reported to be associated with a reduced risk of the disease. More...
To see if treatment with bisphosphonates would correlate with reduced risk for other types of cancer, investigators at the Technion--Israel Institute of Technology (Haifa, Israel) evaluated the use of bisphosphonates with the risk for developing colorectal cancer.

Data on the long-term use of bisphosphonates before diagnosis by 1,866 postmenopausal female participants was extracted from the Molecular Epidemiology of Colorectal Cancer (MECC) study, a population-based case-control study in northern Israel.

Results published in the February 14, 2011, online edition of the Journal of Clinical Oncology revealed that the use of bisphosphonates for more than one year before diagnosis, but not for less than one year, was associated with a significantly reduced relative risk of colorectal cancer. This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones.

Overall, the use of oral bisphosphonates for more than one year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.

"We formerly identified a new class of drugs associated with a reduced risk of breast cancer,” said first author Dr. Gad Rennert, professor of medicine at the Technion--Israel Institute of Technology. "And, now, by showing a similar effect on colorectal cancer risk reduction, we can assume that this class of medications has a broad effect - not necessarily limited to a specific cancer site.”

"While the disease is generally caused by bad dietary habits and lack of physical activity, it can possibly be prevented by several medications, such as aspirin and cholesterol-lowering medication of the statins group,” said Dr. Rennert. "And now, we can add bisphosphonates to the list of tools for potential prevention of colorectal cancer.”

Related Links:

Technion-Israel Institute of Technology



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.